Thymidine Phosphorylase and VEGF in Bladder Cancer
Author Information
Author(s): Brown N S, Streeter E H, Jones A, Harris A L, Bicknell R
Primary Institution: Cancer Research UK, Weatherall Institute of Molecular Medicine, University of Oxford
Hypothesis
Can thymidine phosphorylase activity and hypoxia cooperatively increase VEGF production in bladder cancer cells?
Conclusion
Thymidine phosphorylase activity increases tumorigenicity in bladder cancer, and combining an antioxidant with anti-VEGF therapy can reduce this effect.
Supporting Evidence
- Thymidine phosphorylase activity increases oxidative stress and VEGF secretion in bladder cancer cells.
- Combination therapy with NAC and anti-VEGF antibody significantly reduced tumorigenicity in vivo.
- Elevated thymidine phosphorylase correlates with poor prognosis in bladder cancer.
Takeaway
This study found that a substance called thymidine phosphorylase makes bladder cancer cells grow more aggressively, but using a special medicine can help slow it down.
Methodology
The study involved in vitro experiments with bladder cancer cell lines and in vivo implantation into athymic rats to assess tumorigenicity.
Potential Biases
Potential bias in the selection of cell lines and the experimental model used.
Limitations
The study's findings may not be generalizable beyond the specific cell lines and conditions tested.
Participant Demographics
Nude athymic rats were used for in vivo experiments.
Statistical Information
P-Value
0.03
Statistical Significance
p=0.03
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website